Unavailable
Unavailable
Save time and jump to the most important pieces.
4 - NANOVIRICIDES, INC. (0001379006) (Issuer)
4 - NANOVIRICIDES, INC. (0001379006) (Issuer)
4 - NANOVIRICIDES, INC. (0001379006) (Issuer)
10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)
10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)
8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.Event Information:EventNanoViricides Presentation at the Biotech Showcase, San FransiscoDay & DateTuesday, January 14, 2025Time, Track & Room2:30pm PT, Yosemite A (Ballroom Level)LocationHilton San Fransisco - Union SquareAnil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline a
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going around already.This season, two different genotypes of H5N1 bird flu, namely (a) the severe and lethal form D1.1 that has spread globally in birds, and (b) the less severe B3.13 genotype widely spread in diary cattle in North America are causing major concerns even as Seasonal Influenza cases abound.In addition to that, in the USA, and globally, there are significant numbers of cases of COVID-19, RSV, and hMPV as expected seasonally, that cause various respiratory syndromes from common colds
SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug."Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."WHO has stated "Available virus
SC 13G/A - NANOVIRICIDES, INC. (0001379006) (Subject)